Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

DCC-3009

Stage Phase 1/2

Sponsor Deciphera Pharmaceuticals

Target KIT (TEC-0117)

Sources

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/40368739/

PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.

Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06630234

A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06630234

Registry NCT06630234

Phase Phase 1/2

Status Recruiting

Enrollment 120

Start 2024-12-10

Primary completion 2028-05

Study completion 2028-05

Catalyst Primary completion. 05.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.